PRESS RELEASE 11.6.2025
Publication deadline: 11.6.2025 at 10.00 a.m.
Wellpro Impact Solutions Oy has signed a two-year cooperation agreement with global pharmaceutical giant Boehringer Ingelheim. The agreement concerns the implementation of BitHabit digital tools in an impact-based health programme in the North Savo Wellbeing Region, which is developing the treatment of type 2 diabetes (T2D). Boehringer Ingelheim is one of the world’s largest and longest-lasting family-owned pharmaceutical companies.
This is a major international head start for a Jyväskylä-based wellness technology company. “This is an important step for us, above all from the point of view of impact. We have developed BitHabit to give everyone the opportunity to improve their wellbeing with small actions that have been proven to be effective,” says Petteri Sveins, CEO of Wellpro.
BitHabit – the interface to a better life
BitHabit is a science-based digital lifestyle intervention tool that brings support and information into the user’s everyday life – directly to the smartphone. BitHabit provides users with concrete, personalised ways to support medication management, prevent disease worsening and improve quality of life.
A project launched in North Savo is evaluating the effectiveness of BitHabit as part of the comprehensive treatment of type 2 diabetes. Participants will be offered personalised lifestyle recommendations and monitored for changes in their health status for a year.
“The lessons learned from this health programme on the treatment of type 2 diabetes can be widely used in the future to treat other lifestyle diseases, such as cardiovascular disease, memory problems or obesity. My vision and vision is that every time a person receives a prescription for a medicine for blood pressure, cholesterol or weight management, for example, a QR code could be included in the medicine package, giving the patient access to a digital tool to support their own well-being. In this way, the medicine is accompanied by a tangible opportunity to make a difference to their health – one small action at a time.” Petteri concludes.
An export of well-being from Finland to the world
The cooperation agreement with Boehringer Ingelheim is just the beginning. Negotiations on international expansion are already underway. Boehringer has operations in more than 130 countries, and the common goal with Wellpro is to develop and scale good treatment practices to global markets.
BitHabit is not a medical device, but a mobile tool that promotes health and well-being. It is not a substitute for medicines, but it supports their effectiveness and above all helps people to take concrete steps towards a healthier everyday life.
Background on the project
The North Savo Wellbeing Region and the Diabetes Association are collaborating on a project to develop impact-based T2D care, with BitHabit as a key tool. The number of people with type 2 diabetes is growing in Finland and internationally, and new solutions are needed to develop treatment. The University of Eastern Finland is responsible for the scientific research of the project. The aim of the programme is to develop an impact investment model (SIB) for the period 2026-2027 to develop effective and cost-efficient approaches to improve the quality and effectiveness of diabetes care and reduce the incidence of additional diseases. According to the National Diabetes Quality Register, the balance of diabetes care in Northern Savo has already improved, especially for bad cholesterol.
Further information and interview requests
Petteri Sveins
CEO, Wellpro Impact Solutions Oy
petteri.sveins@wellpro.fi | 050 913 4773
